Comparative Pharmacology
Head-to-head clinical analysis: TANZEUM versus TRULICITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TANZEUM versus TRULICITY.
TANZEUM vs TRULICITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist. Increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection: 300 mg every 4 weeks. Administer as 3 consecutive injections of 100 mg each in the same body region (abdomen, thigh, or upper arm).
1.5 mg subcutaneously once weekly, with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 5 days (range 4-6 days), supporting weekly subcutaneous dosing
Terminal elimination half-life approximately 5 days (112–120 hours) after subcutaneous administration, supporting once-weekly dosing.
Renal (79% as unchanged drug), biliary/fecal (minor, ~1%)
Renal: negligible (intact peptide not excreted in urine); Biliary/fecal: peptide backbone catabolized via proteolysis, with amino acids recycled; no biliary excretion of intact drug.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist